ACD-440 by AlzeCure Pharma for Neuropathic Pain (Neuralgia): Likelihood of Approval

ACD-440 is under clinical development by AlzeCure Pharma and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACD-440’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ACD-440 overview

ACD-440 is under development for the treatment of neuropathic pain including painful peripheral polyneuropathy, peripheral mononeuropathy, postherpetic neuralgia (PHN), chemotherapy induced neuropathic pain, nerve injury pain, chronic postoperative neuropathic pain and peripheral neuropathic pain. It is administered via cutaneous route. The drug candidate acts by targeting vanilloid receptor 1.

AlzeCure Pharma overview

AlzeCure Pharma (AlzeCure) is a drug discovery company that develops therapies for the treatment of age related diseases. The company offers diagnostics and medical technologies for the treatment of alzheimer’s disease and others neurodegenerative conditions. It develops ongoing proprietary research projects through preclinical discovery into clinical phase. AlzeCure has identified drug-like small molecule compounds, affecting the trophic signaling pathways. The company will develop and conduct resesarch of its projects to early clinical phase and try to find suitable out-licensing solutions with other pharmaceutical companies for its products. Alzecure is developing several parallel drug candidates based on the three research platforms : NeuroRestore, Alzstatin and Painless. The company works in collaboration with various companies to develop proprietary research projects. AlzeCure is headquartered in Huddinge, Sweden.

For a complete picture of ACD-440’s drug-specific PTSR and LoA scores, buy the report here.